278 Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors

• Rachel C Lynn,
• Purnima Sundar,
• Omar Ali,
• Christina Cheung,
• Shobha Potluri,
• Meritxell Galindo Casas,
• Candace Sims,
• Viola C Lam,
• Aileen Li,
• Jessica Barragan,
• Jessica Briones,
• Esha Afreen,
• Grant Vavra,
• Jia Lu,
• Rowena Martinez,
• Christina Ta,
• Eskedar Nigatu,
• Alexander S Cheung

Affiliations

Rachel C Lynn

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Purnima Sundar

Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA

Omar Ali

1Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK

Christina Cheung

Department of Emergency Medicine, Arrowhead Regional Medical Center, Colton, California, USA

Shobha Potluri

Lyell Immunopharma, South San Francisco, CA, USA

Meritxell Galindo Casas

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Candace Sims

2Lyell Immunopharma, South San Francisco, CA, USA

Viola C Lam

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Aileen Li

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Jessica Barragan

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Jessica Briones

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Esha Afreen

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Grant Vavra

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Jia Lu

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Rowena Martinez

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Christina Ta

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Eskedar Nigatu

Lyell Immunopharma, Inc., South San Francisco, CA, USA

Alexander S Cheung

Lyell Immunopharma, Inc., South San Francisco, CA, USA